Newsroom | 22146 results

DUBLIN--(BUSINESS WIRE)--The "Infectious Diseases Collaboration and Licensing Deals 2019-2025" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of 1,786 infectious diseases deals from 2019 to 2025. Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the worlds leading biopharma companies. The report provides access t...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). “The receipt of Rare Pediatric Disease Designation highlights the significant...

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which rep...

NEW YORK--(BUSINESS WIRE)--Today, Caesars Palace Times Square, the bid from SL Green, Caesars Entertainment, and Roc Nation to bring a state-of-the-art gaming and entertainment destination to 1515 Broadway in Times Square, announced a $2 million commitment to support Callen-Lorde’s existing services in Chelsea and a $3 million commitment to Callen-Lorde Community Health Center for a new Center for Excellence in Sexual Health. The center, located in Hell’s Kitchen, will be designed to expand acc...

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ : IPA), leader dans le domaine des biothérapies pilotées par l'IA, publie une mise à jour importante à la suite de son communiqué de presse du 5 juin 2025. ImmunoPrecise annonce une percée pilotée par l'IA dans la découverte d'un vaccin universel contre la dengue. Cette nouvelle publication détaille la validation en aval de l'épitope identifié lors de cette première annonce, démontrant que la cible vaccinale sélectionnée par calcul est non s...

BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has filed an investor presentation with the U.S. Securities and Exchange Commission (SEC) as a Form 6-K and launched a website, www.VoteSinovac.com, with important information and resources in connection with the upcoming Special Meeting of Shareholders (the “Special Meeting”) to be held on Wednesday, J...

TAMPA, Fla.--(BUSINESS WIRE)--On National HIV Testing Day, CAN Community Health is partnering with Walgreens to support the national ‘Greater Than HIV’ campaign. This initiative provides free, confidential HIV testing at Walgreens locations nationwide on Friday, June 27, 2025. As part of this national initiative, CAN Community Health mobile units will be stationed at select Walgreens locations across the country, offering on-site HIV testing, prevention education, and linkage to care. According...

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also...

WATERTOWN, Mass.--(BUSINESS WIRE)--Corner Therapeutics, an immunotherapy company pioneering novel approaches to cancer and infection, today announced that its Distinguished Scientist, Scientific Co-founder and Board Member, Professor Jonathan Kagan, Ph.D., will deliver an invited oral presentation at the 25th Annual Meeting of the Federation of Clinical Immunology Societies (FOCiS 2025), taking place from June 24 to 27 in Boston, MA. On June 24, as part of the Member Society Symposia: Innate Im...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention...